ADC Therapeutics

Earnings Samsung Biologics posts record 2024 sales, operating profit as it goes global

South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, on Wednesday posted its largest-ever annual sales and operating p...

Bio & Pharma Lotte Biologics eyes first ADC CDMO order in 2025

SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...

IPOs Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut

SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...

Bio & Pharma Samsung Biologics signs initial deal with LigaChem Bio on ADC production

Samsung Biologics Co., the world’s largest contract drugmaker, said on Thursday it has signed an initial agreement with LigaChem Biosciences I...

Bio & Pharma PharmaResearch acquires TuringBio for digital therapeutics

PharmaResearch Co., a South Korean company specializing in regenerative medicine, announced on Wednesday that it acquired TuringBio, an AI-based dig...

Bio & Pharma Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

IPOs Korean biotech Xcell Therapeutics eyes June IPO

South Korean biotech Xcell Therapeutics Inc., a developer of chemically defined media for in vitro cell culture, is aiming for a junior bourse Kosda...

Bio & Pharma Samsung invests in BrickBio in US

Samsung Group announced on Tuesday that its Life Science Fund has invested in the US-based antibody-drug conjugates (ADC) and gene therapy technol...

Bio & Pharma Samsung Biologics signs ADC CDO deal with LegoChem Bio

Samsung Biologics Co. has agreed with South Korean biotech company LegoChem Biosciences Inc. to provide contract development organization (CDO) serv...

Bio & Pharma Celltrion, WuXi XDC to develop new antibody-drug conjugates

South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...

Bio & Pharma Lotte Biologics, NJ Bio to jointly develop ADC

South Korea's Lotte Biologics Co. announced on Monday that it has signed a strategic business agreement with NJ Bio, a US-based preclinical and clin...

Bio & Pharma LegoChem Bio, Janssen sign $1.7 bn ADC licensing deal

LegoChem Biosciences Inc. has signed a blockbuster $1.7 billion deal to license out its proprietary antibody drug conjugate (ADC) candidate to Jasse...

Bio & Pharma SK Pharmteco secures 12 global pharma clients, sets up US R&D center

SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has secured 12 global pharm...

Bio & Pharma Samsung Biologics to double production by 2032; eyes ADCs, M&As

BOSTON – Samsung Biologics Co., the world’s No. 1 contract drugmaker, plans to more than double its total annual production capacity to ...

Bio & Pharma Celltrion to develop Humira biosimilar oral medication with US firm

South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...

Bio & Pharma Lotte Biologics invests in S.Korean bio-venture Pinotbio

South Korea’s Lotte Biologics Co. said on Friday that it has made an equity investment in Pinotbio, Inc. for the development of antibody-drug ...

Bio & Pharma Welt gets second digital therapeutic device approval in S. Korea

South Korea's Ministry of Food and Drug Safety announced on Wednesday that it has approved the cognitive therapy software "WELT-I" developed by We...

Bio & Pharma Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer

South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, h...

Bio & Pharma GC Biopharma to develop mRNA flu vaccine with Canadian pharma

South Korea's GC Biopharma Corp. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).The dr...

Bio & Pharma AIMMED’s Somzz ushers in digital therapeutic device market in Korea

South Korea’s health and drug safety authority has cleared Somzz to treat patients with sleep disorders, a dynamic move that is expected to vi...

Bio & Pharma Hanall Biopharma invests in Interon Labs for brain disease treatments

South Korean pharmaceuticals firm Hanall Biopharma Co. is investing in Interon Laboratories, a US biotech firm that finds and develops treatments fo...

Bio & Pharma Chong Kun Dang, Synaffix ink deal to introduce ADC technology

Chong Kun Dang Pharmaceutical Corp. said on Monday that it has signed a contract with Dutch biotechnology firm Synaffix B.V for the use of antibody-...

Bio & Pharma Celltrion increases its stake in British ADC developer Iksuda

Celltrion Inc. has secured an additional stake in the UK's antibody-drug conjugate (ADC) developer Iksuda Therapeutics.According to Celltrion on Wed...

Bio & Pharma Celltrion develops oral antibody drug with US bio company

South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...

Bio & Pharma Samjin Pharm to undertake joint ADC R&D with Novelty Nobility

SamjinPharmaceutical announced Wednesday that it has signed a joint research agreement with Novelty Nobility Inc., a company specializing in antibod...

Venture capital Korea’s big bio startups to launch $39 mn investment fund

South Korea’s four leading biotech firms plan to launch an investment fund of up to 50 billion won ($39 million) to support smaller domestic b...

Bio & Pharma LegoChem Bio, Amgen sign ADC platform deal for up to $1.2 bn

South Korean pharmaceutical firm LegoChem Biosciences Inc. said on Dec. 23 it has transferred the antibody-drug conjugates (ADC) technology platform...

Bio & Pharma HLB Therapeutics signs contract for COVID vaccine distribution rights

South Korea's pharmaceutical firm HLB Therapeutics Co. said on Monday that it has signed an agreement with the Korea Disease Control and Prevention ...

Bio & Pharma New drug developer Onconic Therapeutics raises $20 mn in Series B

South Korean drug developer Onconic Therapeutics, announced on Friday that it raised 26 billion won ($19.9 million) in Series B funding, with cumula...

Bio & Pharma MDimune signs research agreement with Australian National University

MDimune, a South Korean biotech company, said on Wednesday that it had signed an agreement with the Clear Vision Research (CVR) Lab, a research grou...